• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Who Gets Pott ’ s Puffy Tumor?
Discussion Pott’s puffy tumor (PPT) was first described by Sir Percivall Pott in 1775 and who also described other orthopaedic and oncological diseases subsequently named for him. “It is a subperiosteal abscess of the anterior wall of the frontal sinus associated with underlying frontal osteomyelitis.” The tender edema and swelling of the forehead is the sign of PPT. Associated fever, headache, and rhinorrhea along with similar problems such as postnasal drip or nasal congestion are common. Associated ophthalmological problems include peri-orbital or eyelid edema and/or preseptal cellulitis. Ptosis and di...
Source: PediatricEducation.org - March 1, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

An Ounce of Caution: Superparamagnetic Iron Oxide Nanoparticle Based MRI Contrast Associated Anaphylaxis
Superparamagnetic iron oxide nanoparticles (SPIONs) are increasingly utilized alternatives to gadolinium-based Magnetic Resonance Imaging (MRI) contrast agents in the diagnosis of osteomyelitis in diabetic patients with renal failure [1]. Ferumoxytol is approved by the United States Food and Drug Administration (FDA), the European Medicines Agency, for intravenous (IV) use for iron replacement therapy [1-3]. Ferumoxytol is composed of an iron-carbohydrate complex that minimizes dissociation and appearance of free iron into the serum.
Source: Annals of Allergy, Asthma and Immunology - November 12, 2018 Category: Allergy & Immunology Authors: Alexander J. Heckman, Anjali Agarwal, Keith A. Sacco, Brett T. Hiroto, Pramod K. Guru Tags: Letters Source Type: research

An ounce of caution
Superparamagnetic iron oxide nanoparticles are increasingly used alternatives to gadolinium-based magnetic resonance imaging (MRI) contrast agents in the diagnosis of osteomyelitis in diabetic patients with renal failure.1 Ferumoxytol is approved by the United States Food and Drug Administration and the European Medicines Agency for intravenous use for iron replacement therapy.1 –3 Ferumoxytol is composed of an iron–carbohydrate complex that minimizes dissociation and appearance of free iron into the serum.
Source: Annals of Allergy, Asthma and Immunology - November 12, 2018 Category: Allergy & Immunology Authors: Alexander J. Heckman, Anjali Agarwal, Keith A. Sacco, Brett T. Hiroto, Pramod K. Guru Tags: Letters Source Type: research